Immuno-Oncology

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the phase Ib results of abemaciclib (Verzenio) plus pembrolizumab (Keytruda) for hormone receptor-positive, HER2-negative metastatic breast cancer.

Suresh A. Ramalingam, MD, reflects on recent data in small cell lung cancer and what is on the horizon in the landscape.

H. Jack West, MD, medical director of thoracic oncology, Swedish Cancer Institute of Swedish Medical Center, discusses the latest immunotherapy findings for lung cancer treatment.

George F. Geils, Jr, MD, discussed the clinical efficacy and adverse event management techniques for pembrolizumab as a treatment for patients with classical Hodgkin lymphoma.

Matthew Galsky, MD, discusses the IMvigor130 and CheckMate-901 studies, as well as the future for chemotherapy in bladder cancer.

Liza C. Villaruz, MD, addresses the immunotherapy clinical trials that have informed the treatment of patients with NSCLC and the current state of biomarkers in the field.

The FDA has approved the combination of nivolumab and ipilimumab for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Joshua Bauml, MD, discusses the limitations of PD-L1 and tumor mutational burden as immunotherapy biomarkers in non–small cell lung cancer and emerging biomarkers showing promise in the field.

Petros Grivas, MD, PhD, discusses ongoing clinical trials exploring novel approaches with the potential to change practice in advanced bladder cancer.

Brian I. Rini, MD, discusses atezolizumab plus bevacizumab as an effective frontline combination in renal cell carcinoma, as well as patient reported outcomes with the regimen.

Sumanta Kumar Pal, MD, sheds light on the latest frontline therapeutic options for patients with mRCC and other advancements on the horizon.

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses checkpoint inhibitors in renal cell carcinoma (RCC).

Marina Chiara Garassino, MD, reflects on the first-line approval of osimertinib, recent data with durvalumab, and the promise for combination chemoimmunotherapy in patients with non–small cell lung cancer.

Recently, immuno-oncologists have turned their attention to the role of the second arm of the immune response—the more rough-and-ready innate arm, which serves as the body’s frontline defense against pathogenic invaders and, it seems, cancer.

The FDA has granted a priority review designation to a supplemental biologics license application for first-line pembrolizumab for use in combination with carboplatin/paclitaxel or nab-paclitaxel for the treatment of patients with metastatic squamous non–small cell lung cancer, regardless of PD-L1 expression.

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses combination immunotherapy in the treatment of patients with bladder cancer.

Liza C. Villaruz, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses PD-L1 expression in lung cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of nivolumab (Opdivo) as an adjuvant treatment for adult patients with completely resected melanoma with lymph node involvement or metastatic disease

Kathryn A. Gold, MD, discusses the evolving management of EGFR-mutant non–small cell lung cancer and the latest developments in small cell lung cancer.